Research programme: anti-pleiotrophin monoclonal antibodies - PDL BioPharma
Alternative Names: 3B10; anti-PTN-mAbsLatest Information Update: 03 Jul 2006
At a glance
- Originator PDL BioPharma
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 22 May 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
- 01 Dec 2003 Preclinical trials in Cancer in USA (unspecified route)